Signal transduction drug discovery: Targets, mechanisms and structure-based design

Current Opinion in Drug Discovery and Development

Volumn 3, Issue 5, 2000, Pages 549-564

  Dalgarno, D C ^a   Metcalf III, C A ^a   Shakespeare, W C ^a   Sawyer, T K ^a  

^a ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

Phosphotyrosine; SH2; Signal transduction; Structure based drug design; Tyrosine kinase; Tyrosine phosphatase

Indexed keywords

2 [2 METHYL 5 [4 (4 METHYL 1 PIPERAZINYLMETHYL)BENZAMIDO]ANILINO] 4 (3 PYRIDYL)PYRIMIDINE; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 3 DIMETHYLAMINO 1 PHENYL 6 PYRIDAZONE; 4 (3 ETHYNYLANILINO) 6,7 BIS(2 METHOXYETHOXY)QUINAZOLINE; CGP 77675; DIHYDROCAROLIC ACID; ERBSTATIN; INDOLINE 2 ONE DERIVATIVE; LAVENDUSTIN A; LEFLUNOMIDE; OSI 774; OXADIAZOLE DERIVATIVE; PD 163510; PD 166866; PD 173074; PHOSPHOTYROSINE; PICEATANNOL; PP 1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; PURINE DERIVATIVE; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRIDOPYRIMIDINE DERIVATIVE; PYRROLOPYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; STAUROSPORINE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZD 1839;

ARTICLE; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; MOLECULAR RECOGNITION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 0033774897     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Protein modules and signaling networks
2. Protein tyrosine kinases: Structure, substrate specificity and drug discovery
3. Identification of a transformation-specific antigen induced by an avian sarcoma virus
4. Protein kinase activity associated with avian sarcoma virus src gene product
5. Evidence that the transforming gene of avian sarcoma virus encodes a protein kinase associated with a phosphoprotein
6. Cellular functions regulated by Src family kinases
7. Tyrosine kinases in disease: Overview of kinase inhibitors as therapeutic agents and current drugs In clinical trials
8. Tyrosine kinase inhibitors in cancer
9. Protein kinase inhibitors: Structural determinants for target specificity
10. Current progress towards the development of tyrosine kinase inhibitors as anticancer agents
11. Protein kinase inhibitors: The tyrosine-specific protein kinases
12. Protein-tyrosine phosphatases: Biological function, structural characteristics, and mechanism of catalysis
13. From form to function: Signaling by protein tyrosine phosphatases
14. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene
15. Modular peptide recognition domains In eukaryotic signaling
16. The PTB domain: A modular domain with multiple functions
17. SH3 domains and drug design: Ligands, structure, and biological function
18. The protein date bank
19. Three-dimensional structure of the tyrosine kinase c-Src
20. Crystal structure of the Src family tyrosine kinase Hck
21. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation
22. Autoregulatory mechanisms in protein-tyrosine kinases
23. Structure-based design and synthesis of a novel class of arc SH2 inhibitors
24. Structure-activity relationships of a novel class of arc SH2 inhibitors
25. Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70
26. Structure-based design of a novel series of nonpeptide ligands that bind to the pp60(arc) SH2 domain
27. Structure-based de nevo design and discovery of non-peptide antagonists of the pp60(are) (Src) SH2 domain
28. Preparation of fluoro- and hydroxy-4-(phosphonomethyl)-D,L-phenylaianine suitably protected for solid-phase synthesis of peptides containing hydrolytically stable analogues of O-phosphotyrosine
29. Structure-based design and solid-phase parallel synthesis of phosphorylated nonpeptides to explore hydrophobic binding at the Src SH2 domain
30. Peptide ligands of pp60(c-arc) SH2 domains: A thermodynamic and structural study
31. The formation of a covalent complex between a dipeptide ligand and the arc SH2 domain
32. The selective inactivation of thiol proteases in vitro and in vivo
33. Cysteinyl proteinases and their selective inactivation
34. Cystaine proteases and their inhibitors
35. A Src SH2 selective binding compound inhibits osteoclast-mediated resorption
36. X-ray structure of citrate bound to Src SH2 leads to a high affinity, bone targeted Src SH2 inhibitor
37. Structure-based design of a novel, osteoclast-selective, nonpeptide Src SH2 inhibitor that demonstrates in vivo anti-resorptive activity
38. Discovery of 3-aminobenzyloxycarbonyl as an N-terminal group conferring high affinity to the minimal phosphopeptide sequence recognized by the Grb2-SH2 domain
39. Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain
40. Highly potent inhibitors of the Grb2-SH2 domain
41. 2
42. Structure-based design, synthesis, and X-ray crystallography of a high-affinity antagonist of the Grb2-SH2 domain containing an asparagine mimetic
43. Structure-based design of peptididomimetic ligands of the Grb2-SH2 domain
44. Structure-based design of a non-peptidic antagonist of the SH2 domain of Grb2
45. Phosphotyrosine-containing dipeptides as high-affinity ligands for the p56(Lek) SH2 domain
46. Ligands for the tyrosine kinase p56(Lek) SH2 domain: Discovery of potent dipeptide derivatives with monocharged, nonhydrolyzable phosphate replacements
47. Progress in the development of inhibitors of SH2 domains
48. NMR-based discovery of phosphotyrosine mimetics that bind to the Lck SH2 domain
49. Discovery of a novel potent, and Src family-selective tyrosine kinase inhibitor: Study of Lck- and Fyn-dependent T cell activation
50. A novel inhibitor of the tyrosine kinase arc suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo
51. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
52. Potent and selective inhibitors of the Abl-kinase: Phenylaminopyrimidine (PAP) derivatives
53. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
54. Eploiting chemical libraries, structure, and genomics in the search for kinase inhibitors
55. Combinatorial target-guided ligand assembly: Identification of potent subtype-selective c-Src inhibitors
56. Crystal structure of c-Src reveal features of its autoinhibitory mechanism
57. Crystal structure of Hck in complex with Src family-selective tyrosine kinase inhibitor
58. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family-selective kinase inhibitors
59. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine
60. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
61. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: A key enzyme in angiogenesis
62. Rescue of osteoclast function by transgenic expression of kinase-deficient arc in arc -/- mutant mice
63. Herbimycin A, a pp60(c-arc) tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo
64. Discovery of a novel series of potent and selective substrata-based inhibitors of p60(c-arc) protein tyrosine kinase: Conformational and topographical constraints in peptide design
65. Potent pseudosubstrate-based peptide inhibitors for p60(c-arc) protein tyrosine kinase
66. Engineering Src family protein kinases with unnatural nucleotide specificity
67. Generation of monospecific nanomolar tyrosine kinase inhibitors via a chemical genetic approach
68. Cell-specific calcineurin inhibition by a modified cyclosporin
69. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity
70. Protein-tyrosine phosphateses: Structure, mechanism, and inhibitor discovery
71. Phosphatoquinones A and B, novel tyrosine phosphatase inhibitors produced by Streptomyces sp
72. CD45 Tyrosine phosphatase inhibitory components from Aspergillus niger
73. Pulchellalactam: A CD45 protein tyrosine phosphatase inhibitor from the marine fungus Corollospora pulchella
74. 1002 Protein tyrosine phosphatases?
75. Cloning of a cDNA for a major human protein-tyrosine phosphatase
76. Osmotic loading of neutralizing antibodies demonstrates a role for protein tyrosine phosphatase 1B in negative regulation of the insulin action pathway
77. Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction
78. Alteretions in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes
79. Skeletal muscle protein tyrosine phosphatase activity and tyrosine phosphatase 1B protein content are associated with insulin action and resistance
80. Small molecule interactions with protein-tyrosine phosphatase PTP1B and their use in inhibitor design
81. Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B
82. Identification of a secondary aryl phosphate-binding site in protein-tyrosine phosphatase 1B: A paradigm for inhibitor design
83. PTB1B Inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes
84. Structure-based discovery of small molecule inhibitors targeted to protein tyrosine phosphatase 1B
85. 2-(Oxaylamino)-benzoic acid is a general, competitive inhibitor of protein-tyrosine phosphateses
86. Structure-based design of low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase. 1B
87. New azolidinediones as inhibitors of protein tyrosine phosphatase 1B with anti-hyperglycemic properties
88. Synthesis and biological evaluation of a targeted library of protein phosphatase inhibitors